Oppenheimer Reiterates Outperform on Viking Therapeutics, Maintains $138 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson has reiterated an Outperform rating for Viking Therapeutics (NASDAQ:VKTX) and maintained a price target of $138.
September 25, 2024 | 5:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Jay Olson has reiterated an Outperform rating for Viking Therapeutics and maintained a price target of $138, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and a high price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in VKTX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100